$INSP
Inspire Medical Systems, Inc.

2021 Q1 Form 10-Q Financial Statement

#000160955021000021 Filed on May 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $40.35M $21.35M
YoY Change 89.03% 31.37%
Cost Of Revenue $5.981M $3.297M
YoY Change 81.41% 15.52%
Gross Profit $34.37M $18.05M
YoY Change 90.42% 34.74%
Gross Profit Margin 85.18% 84.56%
Selling, General & Admin $41.91M $29.05M
YoY Change 44.27% 48.44%
% of Gross Profit 121.93% 160.94%
Research & Development $8.154M $5.438M
YoY Change 49.94% 108.91%
% of Gross Profit 23.72% 30.13%
Depreciation & Amortization $234.0K $187.0K
YoY Change 25.13% 81.55%
% of Gross Profit 0.68% 1.04%
Operating Expenses $50.06M $34.49M
YoY Change 45.14% 55.55%
Operating Profit -$15.69M -$16.44M
YoY Change -4.57% 87.31%
Interest Expense $523.0K $525.0K
YoY Change -0.38% -2.23%
% of Operating Profit
Other Income/Expense, Net -$504.0K $195.0K
YoY Change -358.46% -61.84%
Pretax Income -$16.19M -$16.25M
YoY Change -0.32% 96.53%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$16.22M -$16.25M
YoY Change -0.18% 96.53%
Net Earnings / Revenue -40.19% -76.1%
Basic Earnings Per Share -$0.60
Diluted Earnings Per Share -$0.60 -$672.3K
COMMON SHARES
Basic Shares Outstanding 27.14M shares 24.13M shares
Diluted Shares Outstanding 27.14M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $226.1M $135.7M
YoY Change 66.62% -23.33%
Cash & Equivalents $182.3M $76.12M
Short-Term Investments $43.80M $59.60M
Other Short-Term Assets $1.600M $1.400M
YoY Change 14.29% 0.0%
Inventory $11.39M $7.245M
Prepaid Expenses $1.609M $1.429M
Receivables $21.65M $11.03M
Other Receivables $0.00 $0.00
Total Short-Term Assets $260.8M $155.4M
YoY Change 67.78% -22.0%
LONG-TERM ASSETS
Property, Plant & Equipment $6.791M $3.113M
YoY Change 118.15% 219.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.100M
YoY Change
Other Assets $200.0K $400.0K
YoY Change -50.0% 300.0%
Total Long-Term Assets $12.63M $10.31M
YoY Change 22.55% 1150.61%
TOTAL ASSETS
Total Short-Term Assets $260.8M $155.4M
Total Long-Term Assets $12.63M $10.31M
Total Assets $273.4M $165.7M
YoY Change 64.97% -17.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.100M $5.800M
YoY Change 56.9% 81.25%
Accrued Expenses $10.37M $7.896M
YoY Change 31.27% 2.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.42M $13.72M
YoY Change 41.59% 22.81%
LONG-TERM LIABILITIES
Long-Term Debt $24.80M $24.60M
YoY Change 0.81% 0.82%
Other Long-Term Liabilities $97.00K $40.00K
YoY Change 142.5%
Total Long-Term Liabilities $97.00K $40.00K
YoY Change 142.5% -99.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.42M $13.72M
Total Long-Term Liabilities $97.00K $40.00K
Total Liabilities $50.28M $38.33M
YoY Change 31.17% 6.2%
SHAREHOLDERS EQUITY
Retained Earnings -$253.6M -$196.4M
YoY Change 29.11% 26.56%
Common Stock $27.00K $24.00K
YoY Change 12.5% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $223.1M $127.4M
YoY Change
Total Liabilities & Shareholders Equity $273.4M $165.7M
YoY Change 64.97% -17.17%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$16.22M -$16.25M
YoY Change -0.18% 96.53%
Depreciation, Depletion And Amortization $234.0K $187.0K
YoY Change 25.13% 81.55%
Cash From Operating Activities -$10.40M -$14.78M
YoY Change -29.6% 35.03%
INVESTING ACTIVITIES
Capital Expenditures $1.321M $255.0K
YoY Change 418.04% -7.27%
Acquisitions
YoY Change
Other Investing Activities $0.00 $67.50M
YoY Change -100.0% 315.9%
Cash From Investing Activities -$1.321M $67.24M
YoY Change -101.96% 321.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $3.550M $787.0K
YoY Change 351.08% -315.03%
NET CHANGE
Cash From Operating Activities -$10.40M -$14.78M
Cash From Investing Activities -$1.321M $67.24M
Cash From Financing Activities $3.550M $787.0K
Net Change In Cash -$8.170M $53.26M
YoY Change -115.34% 1043.59%
FREE CASH FLOW
Cash From Operating Activities -$10.40M -$14.78M
Capital Expenditures $1.321M $255.0K
Free Cash Flow -$11.72M -$15.03M
YoY Change -22.01% 33.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001609550
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-38468
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Inspire Medical Systems, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1377674
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5500 Wayzata Blvd.
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1600
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Golden Valley
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55416
CY2021Q1 dei City Area Code
CityAreaCode
844
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
672-4357
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
43796000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
43844000 USD
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021Q1 dei Trading Symbol
TradingSymbol
INSP
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27213528 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
182348000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190518000 USD
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
42000 USD
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27069276 shares
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21646000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25063000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
11385000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8479000 USD
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1609000 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1965000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
260784000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
269869000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6791000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5311000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5634000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5805000 USD
CY2021Q1 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
204000 USD
CY2020Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
204000 USD
CY2021Q1 us-gaap Assets
Assets
273413000 USD
CY2020Q4 us-gaap Assets
Assets
281189000 USD
CY2021Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
9057000 USD
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7209000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10365000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13516000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19422000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20725000 USD
CY2021Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
24804000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24746000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5959000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5886000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
97000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
85000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
50282000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
51442000 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27203073 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27203073 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27069276 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
476658000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
467038000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
29000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253563000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237347000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
223131000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
229747000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
273413000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281189000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40352000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21347000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5981000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3297000 USD
CY2021Q1 us-gaap Gross Profit
GrossProfit
34371000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
18050000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8154000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5438000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41906000 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29052000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
50060000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
34490000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15689000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16440000 USD
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
57000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
642000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
523000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
525000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
78000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-504000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
195000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16193000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16245000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16216000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-16245000 USD
CY2021Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-20000 USD
CY2020Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
193000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16236000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16052000 USD
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27144361 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24165875 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
229747000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3550000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5997000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16216000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
223131000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
139835000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
787000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2749000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
193000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-16245000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
127403000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16216000 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-16245000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
234000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
187000 USD
CY2021Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
30000 USD
CY2020Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
80000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
58000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
54000 USD
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
171000 USD
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
243000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5997000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2749000 USD
CY2021Q1 insp Sharebased Compensation Noncash Services
SharebasedCompensationNoncashServices
73000 USD
CY2020Q1 insp Sharebased Compensation Noncash Services
SharebasedCompensationNoncashServices
72000 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
8000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
89000 USD
CY2021Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-3381000 USD
CY2020Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-2092000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2905000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1411000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-356000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-775000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1477000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1372000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3049000 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4494000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10401000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14775000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1321000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
255000 USD
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
14907000 USD
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 USD
CY2020Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
82403000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1321000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67241000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3550000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
787000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3550000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
787000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8170000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53257000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190518000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22860000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
182348000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76117000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
466000 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
471000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1209000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. We use significant judgment when making estimates related to the allowance for credit losses, inventory reserves, warranty reserves, and stock-based awards. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2021Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0.0 USD
CY2020Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
100000 USD
CY2021Q1 insp Investments Allowance For Credit Loss
InvestmentsAllowanceForCreditLoss
0 USD
CY2020Q4 insp Investments Allowance For Credit Loss
InvestmentsAllowanceForCreditLoss
0 USD
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0 USD
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0 USD
CY2021Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2021Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0 USD
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2021Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0 USD
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of March 31, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div>
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1419000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
892000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
9966000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7587000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
11385000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
8479000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000 USD
CY2021Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000 USD
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8859000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7156000 USD
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2068000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1845000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6791000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5311000 USD
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 USD
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 USD
CY2021Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
8301000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
11965000 USD
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
160000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
160000 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1904000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1391000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10365000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13516000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Advertising Expense
AdvertisingExpense
9000000.0 USD
CY2020Q1 us-gaap Advertising Expense
AdvertisingExpense
6400000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 USD
CY2021Q1 insp Operating Leases Future Minimum Payments Net Present Value
OperatingLeasesFutureMinimumPaymentsNetPresentValue
7400000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5634000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5805000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5959000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5886000 USD
CY2021Q1 insp Operating Lease Remaining Lease Term
OperatingLeaseRemainingLeaseTerm
P7Y2M12D
CY2021Q1 insp Operating Lease Remaining Lease Discount Rate Percent
OperatingLeaseRemainingLeaseDiscountRatePercent
0.052
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
300000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9188000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12250000 USD
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
3062000 USD
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
24500000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5997000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2749000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5997000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2749000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2857564 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
66.09
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
351626000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
68802 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
207.15
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
133421 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
26.61
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
24567000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
42570 shares
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
111.03
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2750375 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
70.84
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
374706000 USD
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1221474 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.27
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2021Q1 insp Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable
223188000 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
72400000 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40352000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21347000 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2758435 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2625789 shares

Files In Submission

Name View Source Status
0001609550-21-000021-index-headers.html Edgar Link pending
0001609550-21-000021-index.html Edgar Link pending
0001609550-21-000021.txt Edgar Link pending
0001609550-21-000021-xbrl.zip Edgar Link pending
a2021-q1ex31x1.htm Edgar Link pending
a2021-q1ex31x2.htm Edgar Link pending
a2021-q1ex32x1.htm Edgar Link pending
a2021-q1ex32x2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
insp-20210331.htm Edgar Link pending
insp-20210331.xsd Edgar Link pending
insp-20210331_cal.xml Edgar Link unprocessable
insp-20210331_def.xml Edgar Link unprocessable
insp-20210331_g1.jpg Edgar Link pending
insp-20210331_htm.xml Edgar Link completed
insp-20210331_lab.xml Edgar Link unprocessable
insp-20210331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending